Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Introduction: Lung cancer is the leading cause of cancer death in Australia and has the highest cancer burden. Numerous reports describe variations in lung cancer care and outcomes across Australia. There are no data assessing compliance with treatment guidelines and little is known about lung cancer multidisciplinary team (MDT) infrastructure around Australia.
Methods: Clinicians from institutions treating lung cancer were invited to complete an online survey regarding the local infrastructure for lung cancer care and contemporary issues affecting lung cancer.
Results: Responses from 79 separate institutions were obtained representing 72% of all known institutions treating lung cancer in Australia. Most (93.6%) held a regular MDT meeting although recommended core membership was only achieved for 42/73 (57.5%) sites. There was no thoracic surgery representation in 17/73 (23.3%) of MDTs and surgery was less represented in regional and low case volume centres. Specialist nurses were present in just 37/79 (46.8%) of all sites. Access to diagnostic and treatment facilities was limited for some institutions. IT infrastructure was variable and most sites (69%) do not perform regular audits against guidelines. The COVID-19 pandemic has driven most sites to incorporate virtual MDT meetings, with variable impact around the country. Clinician support for a national data-driven approach to improving lung cancer care was unanimous.
Discussion: This survey demonstrates variations in infrastructure support, provision and membership of lung cancer MDTs, in particular thoracic surgery and specialist lung cancer nurses. This heterogeneity may contribute to some of the well-documented variations in lung cancer outcomes in Australia.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8765035 | PMC |
| http://dx.doi.org/10.1136/bmjresp-2021-001157 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Enantioselective Synthesis of Spirooxindole Derivatives through Lewis Acid-Catalyzed Michael Addition/Cyclization Cascade.
J Org Chem
September 2025
Department of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan University, School of Pharmaceutical Sciences, Wuhan University, Wuhan 430071, P. R. of China.
A Mg(OTf)-catalyzed asymmetric Michael addition/cyclization cascade reaction between 3-isothiocyanato oxindoles and 2-arylidene-1,3-indanediones has been developed. This transformation provides an efficient and concise approach to biologically important bispiro[indanedione-oxindole-pyrrolidinyl]s under mild conditions in good to excellent yields (70-99% yields) with moderate to good stereoselectivities (up to 99% and >95:5 d.r.
View Article and Find Full Text PDFExpanded senescent CD8 T-cells in IMID patients are associated with distinct inflammatory cytokines.
Clin Exp Immunol
September 2025
Rheumatology Department, Université Paris-Saclay, Institut National de la Santé et de la Recherche Médicale (INSERM) UMR1184, Hôpital Bicêtre, Assistance Publique-Hôpitaux de Paris (APHP), CEA , FHU CARE, Le Kremlin Bicêtre, France.
Introduction: Immunosenescence remodels immune functions and was first described with aging. It is present in 25% of cancer patients but has also been described in patients with Immune-mediated inflammatory diseases (IMIDs). This study aims at quantifying cells exhibiting a phenotype of senescence in CD4+ (T4sen) and CD8+ (T8sen) T cells, analyzing its potential drivers and the effect of anti-TNF treatment in a prospective cohort of patients with rheumatoid arthritis (RA), spondyloarthritis (SpA) and Sjögren disease (SjD).
View Article and Find Full Text PDFO-GlcNAcylated YTHDF2 promotes bladder cancer progression by regulating the tumor suppressor gene via mA modification.
Zhong Nan Da Xue Xue Bao Yi Xue Ban
May 2025
Department of Urology, Second Xiangya Hospital, Central South University, Changsha 410011, China.
Objectives: Bladder cancer is a common malignancy with high incidence and poor prognosis. N-methyladenosine (mA) modification is widely involved in diverse physiological processes, among which the mA recognition protein YTH N-methyladenosine RNA binding protein F2 (YTHDF2) plays a crucial role in bladder cancer progression. This study aims to elucidate the molecular mechanism by which O-linked -acetylglucosamine (O-GlcNAc) modification of YTHDF2 regulates its downstream target, period circadian regulator 1 (), thereby promoting bladder cancer cell proliferation.
View Article and Find Full Text PDFRadiogenomics-based prediction of and gene mutation in non-small cell lung cancer patients.
Zhong Nan Da Xue Xue Bao Yi Xue Ban
May 2025
Department of Geriatric Pulmonary and Critical Care Medicine, Xiangya Hospital, Central South University; National Clinical Research Center for Geriatric Disorders (Xiangya Hospital), Changsha 410008.
Objectives: Non-small cell lung cancer (NSCLC) is associated with poor prognosis, with 30% of patients diagnosed at an advanced stage. Mutations in the and genes are important prognostic factors for NSCLC, and targeted therapies can significantly improve survival in these patients. Although tissue biopsy remains the gold standard for detecting gene mutations, it has limitations, including invasiveness, sampling errors due to tumor heterogeneity, and poor reproducibility.
View Article and Find Full Text PDFCD63 is a diagnostic marker of prostate cancer and a prognostic marker of biochemical progression following radical prostatectomy.
Histol Histopathol
September 2025
Institute of Pathology, University Hospital Bonn, Bonn, Germany.
Aims: We aimed to analyze CD63, a cell surface protein that has been associated with tumor aggressiveness in several cancers, including breast, colorectal, and lung cancer, as well as melanoma, in prostate cancer.
Methods: CD63 expression was analyzed immunohistochemically in a cohort of primary prostate cancers from 281 patients. The results were correlated with clinico-pathologic parameters, including biochemical recurrence.